Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
OLEMA PHARMACEUTICALS INC reports FMR LLC beneficial ownership of 9,998,059.72 shares of common stock, representing 12.5% of the class. The filing (Amendment No. 1 to a Schedule 13G) shows FMR LLC has sole dispositive power for 9,998,059.72 shares and sole voting power of 9,985,722 shares.
Abigail P. Johnson is also listed with sole dispositive power for 9,998,059.72 shares. The filing notes that one or more other persons have rights to dividends or proceeds but no other single person holds over 5%.
Olema Pharmaceuticals’ chief legal officer Mitchell Shawnte reported option exercises and related stock sales. On March 3–4, 2026, she exercised options for a total of 40,000 shares of common stock at $4.37 per share and sold 40,000 shares in open-market transactions at weighted average prices around the mid‑$20s. Following these trades, she reported 410,000 stock options outstanding and no directly held common shares.
Olma Health affiliate transactions: Shane W. Kovacs reported multiple sales of Common stock totaling several tranches in January–February 2026. The filing lists individual sales such as 100,000 shares on 01/15/2026 and smaller tranches on other dates, with cash proceeds shown per trade.
Shawnte M. Mitchell reported insider transactions related to common stock of the issuer. The filing shows a sale of 15,000 common shares on 03/03/2026 for $345,153. It also lists a proposed sale of 25,000 common shares through Fidelity Brokerage Services LLC on 03/04/2026, arising from an option granted on 02/28/2025, to be sold for cash.
Shane W. Kovacs reported proposed sales of Common Stock on Form 144 handled through Fidelity Brokerage Services LLC. The filing lists recent dispositions in the past three months: 01/15/2026 sale of $2,873,214.99 (100,000 shares), 02/23/2026 sale of $723,007.46 (30,000 shares), 02/24/2026 sale of $500,002.00 (20,000 shares), 02/12/2026 sale of $238,498.19 (10,000 shares) and an earlier 01/13/2026 entry of $107,069.20 (3,822 shares). The filing identifies the broker as Fidelity Brokerage Services LLC.
Olami Medical submitted a Form 144 notice reporting a proposed resale of 20,000 common shares on 02/24/2026. The filing lists the securities as restricted stock that vested on 06/15/2020 and shows multiple recent sales by Shane W. Kovacs totaling 143,822 shares across dates in 01/2026 and 02/2026.
OLMA Form 144 filing reports proposed and recent sales of common stock by an insider. The excerpt shows Shane W. Kovacs sold 3,822 shares on 01/13/2026, 100,000 shares on 01/15/2026, and 10,000 shares on 02/12/2026, with dollar amounts listed for each sale. The filing also lists 10,000 shares associated with Fidelity Brokerage Services LLC dated 02/23/2026.
OLMA filer submitted a Form 144 reporting a proposed sale of 20,000 common shares by Fidelity Brokerage Services LLC. The filing also discloses recent reported sales by Shane W. Kovacs, including a sale of 100,000 shares for $2,873,214.99 on 01/15/2026 and 10,000 shares for $238,498.19 on 02/12/2026.
Olema Pharmaceuticals reported that its VP of Finance and Controller, Sasha Lu Austin, acquired equity awards on February 2, 2026. The awards include a stock option for 29,250 shares at an exercise price of $0.00 and a grant of 11,700 shares of common stock, both recorded as awards rather than open-market purchases.
According to the vesting terms, 25% of the option shares vest on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. All holdings are reported as direct ownership.